UBS O'Connor’s Arcturus Therapeutics ARCT Stock Holding History

UBS O'Connor’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-7,143	Closed	-$314K	–	442
2015 Q4	$314K	Buy	+7,143	New	+$322K	﹤0.01%	396

Other funds holding ARCT

Franklin Resources

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Alyeska Investment Group

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

UBS O'Connor's ARCT Position: Q1 2016 in Review

UBS O'Connor sold out of Arcturus Therapeutics (ARCT) in Q1 2016, closing a stake of 7,143 shares — an estimated $314K sold.

UBS O'Connor first reported a position in ARCT in Q4 2015 and held it in 1 quarter. The position peaked at $314K in Q4 2015. 46 funds tracked by Wall St. Rank hold ARCT as of Q1 2016.

UBS O'Connor reported no remaining Arcturus Therapeutics position as of Q1 2016 after selling out during the quarter.
UBS O'Connor sold 7,143 Arcturus Therapeutics shares in Q1 2016, an estimated $314K.
UBS O'Connor first reported a position in Arcturus Therapeutics in Q4 2015 and held it in 1 quarter.
UBS O'Connor's Arcturus Therapeutics position peaked at $314K in Q4 2015.
46 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q1 2016.

Based on UBS O'Connor's 13F filing for Q1 2016, filed 13 May 2016.